Akèy › Maladi otoim › Massachusetts › Boston
Etid klinik pou Maladi otoim nan Boston, MA
13 etid pou Maladi otoim ap chèche patisipan nan sit nan ak bò kote Boston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
Ap rekriteFaz 3
- Tufts Medical Center, Boston
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Ap rekriteFaz 1
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Ap rekriteFaz 3
- Massachusetts General Hospital, Boston
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Ap rekriteFaz 2/3
- Boston Children's Hospital - Accepting Young Adults and Juvenile Patients, Boston
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Ap rekriteFaz 3
- Massachusetts General Hospital, Boston
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Ap rekriteFaz 1/2
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Boston Children's Hospital, Boston
- ak 1 plis
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Ap rekriteFaz 1/2
- Beth Israel Deaconess Medical Center, Boston
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Ap rekriteFaz 3
- Boston Children's Cancer Center, Boston
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Ap rekriteFaz 1
- Brigham And Womens Hospital, Boston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
Ap rekriteFaz 1
- Tufts University, Boston
- Massachusetts General Hospital, Boston
- Brigham and Women's Hospital, Boston
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Ap rekriteFaz 1/2
- Brigham and Women's Hospital, Boston
Testimonials and Navigation in Rheumatology
Ap rekrite
- Brigham Women's Hospital, Boston
Etid Maladi otoim nan lòt vil
- Houston, TX21 etid
- Washington, DC19 etid
- New York City, NY19 etid
- Philadelphia, PA16 etid
- Durham, NC15 etid
- Los Angeles, CA12 etid
- Chicago, IL12 etid
- Dallas, TX9 etid
- Cleveland, OH8 etid
- Milwaukee, WI8 etid
- Atlanta, GA8 etid
- Portland, OR8 etid
Lòt etid nan Boston
- Kansè nan tete111 etid
- Kansè Poumon ki pa ti selil90 etid
- Kansè (tout kalite)86 etid
- Kansè kolorektal63 etid
- Kansè Metastatik63 etid
- Kansè poumon62 etid
- Kansè ovè61 etid
- Kansè pwostat59 etid
- Depresyon52 etid
- Kansè Endomèt50 etid
- Ensifizyans kadyak44 etid
- Leksemi mieloïd egi44 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.